Whanin Pharm (016580) — Capital Reinvestment Ratio
Whanin Pharm (016580) has a Capital Reinvestment Ratio of 0.11x as of June 2026, meaning it reinvests 0% of its operating cash flow (₩9.26 Billion) in capital expenditures (₩1.01 Billion). Check how tangible is Whanin Pharm's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Whanin Pharm Capital Reinvestment Ratio (2009–2025)
This chart tracks Whanin Pharm's Capital Reinvestment Ratio across 14 annual periods. For the full cash flow conversion analysis, see 016580 cash flow conversion.
Annual Capital Reinvestment Ratio for Whanin Pharm (2009–2025)
Year-by-year Capital Reinvestment Ratio for Whanin Pharm from 2009 to 2025. See Whanin Pharm free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.68x | ₩9.04 Billion | ₩6.18 Billion | ▼ -51.9% |
| 2024 | 1.42x | ₩20.69 Billion | ₩29.38 Billion | ▲ +4.6% |
| 2023 | 1.36x | ₩23.20 Billion | ₩31.49 Billion | ▼ -32.0% |
| 2022 | 2.00x | ₩16.85 Billion | ₩33.65 Billion | ▲ +1507.6% |
| 2021 | 0.12x | ₩35.32 Billion | ₩4.39 Billion | ▼ -64.6% |
| 2020 | 0.35x | ₩22.75 Billion | ₩7.99 Billion | ▲ +214.5% |
| 2019 | 0.11x | ₩24.73 Billion | ₩2.76 Billion | ▼ -52.5% |
| 2018 | 0.23x | ₩17.45 Billion | ₩4.10 Billion | ▼ -71.4% |
| 2017 | 0.82x | ₩23.48 Billion | ₩19.31 Billion | ▲ +118.5% |
| 2016 | 0.38x | ₩19.82 Billion | ₩7.46 Billion | ▲ +57.1% |
| 2012 | 0.24x | ₩21.11 Billion | ₩5.06 Billion | ▲ +35.2% |
| 2011 | 0.18x | ₩15.12 Billion | ₩2.68 Billion | ▲ +0.0% |
| 2010 | 0.18x | ₩15.12 Billion | ₩2.68 Billion | ▲ +51.0% |
| 2009 | 0.12x | ₩18.61 Billion | ₩2.18 Billion | — |